What is Axoltis Pharma?
Headquartered in Clermont-Ferrand with a strategic presence in Lyon, Axoltis Pharma operates at the intersection of advanced neurology and drug discovery. The company is primarily focused on the development of NX210c, a lead therapeutic candidate designed to address high unmet medical needs in patients suffering from debilitating neurological conditions. Through a robust network of partnerships with internationally recognized academic institutions and private laboratories, Axoltis integrates deep scientific expertise with a disciplined approach to drug development. Their operational model emphasizes the translation of complex biological research into viable clinical solutions, effectively bridging the gap between laboratory innovation and patient-centric therapeutic applications.
How much funding has Axoltis Pharma raised?
Axoltis Pharma has raised a total of $20.9M across 1 funding round:
Series A
$20.9M
Series A (2025): $20.9M with participation from Cenitz
Key Investors in Axoltis Pharma
Cenitz
CENITZ is a private equity firm that specializes in investing in early-stage healthcare companies and innovative startups across various high-end verticals, focusing on medical devices and digital health solutions.
What's next for Axoltis Pharma?
With the successful closure of this major enterprise-level funding, Axoltis Pharma is expected to prioritize the advancement of its lead product, NX210c, through subsequent clinical milestones. The strategic deployment of these funds will likely focus on expanding internal research capabilities, scaling manufacturing processes for clinical trials, and strengthening the company's intellectual property portfolio. As the firm transitions into a more mature phase of development, the focus will shift toward regulatory engagement and the potential for future commercialization partnerships. This capital infusion provides the necessary runway to navigate the high-barrier entry requirements of the neuro-therapeutic market, ensuring that Axoltis remains at the forefront of neurological innovation.
See full Axoltis Pharma company page
